Semaglutide vs Tirzepatide vs Retatrutide: What’s the Difference?
Semaglutide vs Tirzepatide vs Retatrutide: What's the Difference?
One, two, three hormones — and why the scale drops further with each new drug.
Ten years ago, the phrase "a pill that makes you lose weight" sounded like a promise straight out of a spam folder. Today it's the hottest topic in pharmacology, and the difference between three drugs — semaglutide, tirzepatide and retatrutide — is essentially the story of how science learned to press not one button in your metabolism, but two and then three at once.
Let's sort it out — without the unnecessary Latin, but honestly.
Quick difference:
- Semaglutide — GLP-1 only: appetite and satiety.
- Tirzepatide — GLP-1 + GIP: stronger weight loss and glucose effects.
- Retatrutide — GLP-1 + GIP + glucagon: adds an energy-expenditure angle, but is not approved yet.
How it all started: the satiety hormones
When you eat, your gut releases hormones that tell the brain and pancreas: "Relax, the food has arrived." One of the main ones is GLP-1. It slows down how fast your stomach empties, so fullness lasts longer, it dials down appetite in the brain, and it helps the pancreas release insulin at the right moment.
The catch is that your own GLP-1 survives in the bloodstream for only a few minutes. Scientists built a stable version of it — and that gave birth to a whole family of drugs. Then the race began: how many hormonal "buttons" could one molecule press at the same time.
Generation one: semaglutide — one button
Semaglutide (known under the names Wegovy and Ozempic) is a mono-agonist. It acts on exactly one receptor — GLP-1 — but it does so for a long time and with force.
Picture appetite as having a volume knob, and semaglutide slowly turning it down. The person simply wants to eat less, fills up faster, and thinks about snacks less often. In trials this produced an average of around 15% loss of body weight — a result no pill or injection had delivered before.
That was the moment it became clear that the incretin hormones aren't a minor detail but the main lever.
Generation two: tirzepatide — two buttons
The next step is obvious: if one satiety hormone works, what happens if you add a second?
Tirzepatide (Mounjaro, Zepbound) acts on two receptors at once — GLP-1 and GIP. GIP is another incretin hormone. It strengthens the insulin response, gets involved in how fat tissue works, and seems to smooth out appetite further while also improving tolerability — you get less nausea per unit of effect.
To put it visually: if semaglutide turns one volume knob, tirzepatide turns two at once, and they amplify each other. The result is noticeably stronger — up to 20–22% of body weight in trials. For many patients, that's the line where "lost a bit" ends and a real change in health begins: blood pressure, blood sugar, lab results.
Generation three: retatrutide — three buttons
And this is where it gets most interesting. Retatrutide adds a third target to GLP-1 and GIP — the glucagon receptor. And that's not just "one more hormone on the list"; it's a different philosophy.
All the earlier drugs worked on one side of the equation — reducing how many calories come in. Glucagon touches the other side: how many calories the body spends. It slightly revs up metabolism (raising energy expenditure), breaks down fat more actively, and helps clear fat out of the liver.
The result is a clever combination: two buttons say "eat less," and the third says "burn more." The body gets less fuel and spends its reserves more aggressively at the same time.
The numbers match the ambition. In the pivotal Phase 3 trial TRIUMPH-1, published in May 2026, the average loss was 28.3% of body weight on the 12 mg dose over 80 weeks — already approaching the results of bariatric surgery, only without the scalpel.
There's an elegant twist, too. Glucagon on its own raises blood sugar — which would seem bad for people with diabetes. But the powerful insulin effect of the other two hormones offsets it, and the balance stays on the side of benefit. A separate bonus of the "glucagon" branch is the real hope it offers for treating fatty liver disease.
Why you can't just "crank the volume to maximum"
A logical question follows: if three is better than two, and two is better than one — why not make a drug with five targets and lose the weight in a month?
Because these drugs have a downside, and it scales too. The stronger the effect, the more frequent the gastrointestinal side effects: nausea, vomiting, diarrhea, especially at the start. That's exactly why all three drugs aren't prescribed at the full dose right away — they're introduced through slow titration: you begin with a tiny dose and raise it over weeks and months so the body has time to adjust. It's not a "forgot it — I'll catch up tomorrow" situation, but a careful schedule.
So more receptors don't come for free. It's a stronger result in exchange for more careful dosing and supervision.
The most important part in practice: what's already approved and what isn't
Here's a difference that's easy to miss behind the pretty percentages.
Semaglutide and tirzepatide are approved drugs. A doctor can prescribe them, fine-tune the dose, and supervise the treatment.
Retatrutide, as of mid-2026, is not yet approved: it's going through Phase 3 trials, the regulatory filing is expected toward the end of 2026, and the actual market launch is roughly 2027–2028. Anything sold online right now as "retatrutide" is a gray market with no control over quality, purity, or dosing. The impressive numbers from the trials were obtained under medical supervision and with a pharmaceutically pure drug — which is not the same thing as a vial of unknown contents.
The whole thing in one sentence
Semaglutide taught the body to hear the satiety signal better. Tirzepatide added a second voice to that chorus. Retatrutide doesn't just quiet appetite — it switches on burning, too, which is exactly why it shows the biggest numbers.
It's a beautiful trajectory of progress. But the main rule stays boringly practical: which drug, at what dose, and whether you need it at all is a decision that makes sense to reach together with a doctor — not with a calculator and a vial from the internet.